In a continuation of the previous episode, Mike Drues joins the podcast to further discuss LDTs, IVDs, and how those related to the ongoing Theranos situation.
Mike is the president of Vascular Sciences, has a Ph.D. in biomedical engineering, and has extensive experience with Regulatory Strategy.
In today’s episode, he begins by reviewing some of the information in Part 1 of this discussion. He discusses how the current regulations and language around LDTs relate to the Theranos situation and what companies should be doing to ensure they’re ready when the VALID act goes through.
Listen to this episode to hear what Mike has to say about the risks of LDTs, the engineering work that should go into LDTs, and how the regulations could be changed to close the Theranos loophole.
Like this episode? Subscribe today on iTunes or Spotify.
The risk behind LDTs vs IVDs
Whether LDTs belong in the IVD category
The relationship between the LDT situation and Theranos
Principles to use with LDTs
What companies should be doing now in anticipation of the VALID act
The importance of a contingency plan
The criteria for a legitimate LDT
Specific parameters to define an LDT
Labeling
Technology
Risk
Requiring hospitals to put LDTs through institutional review boards
Better oversight
Creating a EUA-like pathway
“Even from a technology perspective, the technology of these LDTs is becoming much much more complicated.”
“Long story short, I think Theranos took a fairly liberal interpretation of the words surrounding the LDT.”
“I’m a biomedical engineer first and a regulatory consultant second. And that’s the order we should think about these things.”
“Even though I’m a regulatory consultant, I’m not a fan of creating new regulation.”
The Global Medical Device Podcast powered by Greenlight Guru is where today's brightest minds in the medical device industry go to get their most useful and actionable insider knowledge, direct from some of the world's leading medical device experts and companies.